Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Matej Živec"'
Autor:
Izidor Sosič, Irena Mlinarič-Raščan, Samo Lešnik, Damijan Knez, Aleš Obreza, Mitja Ogrizek, Dušanka Janežič, Dušan Žigon, Boris Brus, Martina Gobec, Janez Konc, Stanislav Gobec, Matej Živec
Publikováno v:
Angewandte Chemie International Edition
Elevated expression of the immunoproteasome has been associated with autoimmune diseases, inflammatory diseases, and various types of cancer. Selective inhibitors of the immunoproteasome are not only scarce, but also almost entirely restricted to pep
Autor:
David Barros, Robert J. Young, Roman Šink, Chun-wa Chung, Matej Živec, Daniel Alvarez-Gomez, Emilio Alvarez-Ruiz, Lourdes Encinas, Esther Pérez-Herrán, María Martínez-Hoyos, Stanislav Gobec, Julia Castro-Pichel, Stane Pajk, Alfonso Mendoza-Losana, Margarete Neu, Izidor Sosič, Máire A. Convery, Lluís Ballell-Pages
Publikováno v:
European Journal of Medicinal Chemistry. 112:252-257
Tetrahydropyran derivative 1 was discovered in a high-throughput screening campaign to find new inhibitors of mycobacterial InhA. Following initial in-vitro profiling, a structure-activity relationship study was initiated and a focused library of ana
Publikováno v:
Organic Process Research & Development. 14:1125-1129
Pramipexole is a dopamine D2 subfamily receptor agonist that is used for the treatment of Parkinson’s disease. We report here on the successful application of the Fukuyama alkylation protocol to the development of a novel and scalable process for s
Autor:
Roman Šink, Joaquin Rullas-Triconado, Lluís Ballell-Pages, Eva Maria Lopez-Roman, Robert J. Young, Lourdes Encinas, David Barros, Raquel Fernandez-Menendez, Samo Turk, Matej Živec, Stane Pajk, Izidor Sosič, Stanislav Gobec, Iñigo Angulo-Barturen, Daniel Alvarez-Gomez, Carolina Gonzales-Cortez
Publikováno v:
Journal of medicinal chemistry. 58(2)
Mycobacterial enoyl acyl carrier protein reductase (InhA) is a clinically validated target for the treatment of tuberculosis infections, a disease that still causes the death of at least a million people annually. A known class of potent, direct, and
Autor:
Jan Humljan, Olivier Verlaine, Matej Živec, André Luxen, Astrid Zervosen, Izidor Sosič, Bernard Joris, Stanislav Gobec, Samo Turk, Ana Maria Amoroso, Thomas Gerards
Publikováno v:
PLoS ONE
PLoS ONE, Vol 6, Iss 5, p e19418 (2011)
PLoS ONE, Vol 6, Iss 5, p e19418 (2011)
Background Penicillin-binding proteins (PBPs) are well known and validated targets for antibacterial therapy. The most important clinically used inhibitors of PBPs β-lactams inhibit transpeptidase activity of PBPs by forming a covalent penicilloyl-e
Autor:
Samo Turk, Olivier Verlaine, Thomas Gerards, Matej Zivec, Jan Humljan, Izidor Sosič, Ana Amoroso, Astrid Zervosen, André Luxen, Bernard Joris, Stanislav Gobec
Publikováno v:
PLoS ONE, Vol 6, Iss 5, p e19418 (2011)
BACKGROUND: Penicillin-binding proteins (PBPs) are well known and validated targets for antibacterial therapy. The most important clinically used inhibitors of PBPs β-lactams inhibit transpeptidase activity of PBPs by forming a covalent penicilloyl-
Externí odkaz:
https://doaj.org/article/8739f728de1940b8ac815473f2d0405e